Resident doctors at Delhi’s Ram Manohar Lohia Hospital on Saturday decided to boycott the Covaxin shots. The resident doctors have written to the Medical Superintendent asking to be vaccinated against COVID-19 using the Covishield vaccine instead of Covaxin.
They said they wanted to be administered by the Serum Institute’s Covishield vaccine, instead of being given the Bharat Biotech’s Covaxin vaccine due to apprehensions over lack of complete trial.
Covaxin manufactured by Bharat Biotech is being preferred over Covishield manufactured by Serum Institute in RML hospital.
The doctors also said that Covaxin manufactured by Bharat Biotech was being preferred at the hospital’s vaccination site over Covishield produced by the Serum Institute of India (SII). Covaxin is still undergoing Phase-3 trials.
Covaxin, the COVID-19 vaccine produced by Hyderabad-based Bharat Biotech, is still undergoing Phase-3 trials. India approved the vaccine for emergency use on January 3, but the nod has come under criticism for lack of efficacy data, typically obtained from a large, Phase-3 human trial which the manufacturer is still conducting.
- ICMR study to assess connection between heart attack deaths, Covid
- Meghalaya Cong MP writes to PM to build women’s markets
- EU removes Pakistan from list of ‘High-Risk Third Countries’
- Why the ethics of octopus farming is so troubling
- Spouses of H-1B visa holders can work in US, says judge
- India to unveil new Foreign Trade Policy 2023-28